Mitral Regurgitation Clinical Trial
— Dutch-AMROfficial title:
Dutch-AMR Study: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation and Preserved Ejection Fraction: a Multicenter Registry Trial
NCT number | NCT03975998 |
Other study ID # | 16/743 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 2016 |
Est. completion date | October 2031 |
Verified date | June 2019 |
Source | UMC Utrecht |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Rationale:
Severe asymptomatic organic Mitral Valve (MV) regurgitation with preserved left ventricular
(LV) function is a challenging clinical entity as data on the recommended treatment strategy
for these patients are scarce and conflicting, which is reflected in current guidelines.
European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly
echocardiography, whilst American guidelines are more in favour of early surgery to
reconstruct the MV, i.e. MV repair (in contrast to MV replacement) in order to prevent future
LV dysfunction and complaints.
A number of non-randomised trials show a favourable outcome of early surgery: in the study of
Enriquez-Sarano et al. for instance, the early surgery strategy has shown to be associated
with improved long-term survival, decreased cardiac mortality, and decreased morbidity
compared with the conservative management [1]. On the other hand, non-randomised trials
describe also that a conservative strategy (i.e. watchful waiting) can be safely
accomplished. If facilitated surgery is performed in this population (50% at 10 years
follow-up according to Rosenhek et al [2]), it has proven to be eventually associated with
good perioperative and postoperative outcome when careful follow-up is being carried out [2].
Objective:
To compare early MV repair versus watchful waiting in asymptomatic patients with severe
organic mitral valve regurgitation and preserved left ventricular function.
Study design:
Multicenter, registry trial.
Study population:
250 Asymptomatic patients (18-75 years old) with severe organic MV regurgitation and
preserved left ventricular function. The current European Society of Cardiology (ESC)
guidelines on Valvular Heart Disease will be applied [3]. These guidelines are also used in
the Netherlands. Accordingly, patients with an indication for MV surgery will not be
included.
Intervention:
Intervention will be early MV repair compared to a watchful waiting strategy.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | October 2031 |
Est. primary completion date | October 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - 18-75 years. - Asymptomatic patients. "Asymptomatic" is defined as absence of subjective limitations of exercise capacity or complaints expressed by the patient and confirmed by the treating cardiologist. - Severe organic mitral valve regurgitation. "Severe organic mitral valve regurgitation" is defined as non-ischemic mitral valve regurgitation with an organic cause (intrinsic valve lesion) as determined by echocardiographic core-lab reading based on the criteria for definition of severe MR as issued by the ESC guidelines [4]. For practical reasons, referring cardiologists can use an ESC guidelines based index that was validated in the investigator's core-lab (Jansen et al, Practical echocardiographic semi-quantitative scoring system to determine severity of mitral regurgitation. Abstract presentation at ESC EUROECHO Congress 2011 and annual spring congress 2012 Netherlands Society of Cardiology). - Preserved left ventricular function, "Preserved left ventricular function" is defined as left ventricular ejection fraction >60% and left ventricular end-systolic dimension <45 mm (no indexed value, measured by echocardiography). - The likelihood of MV repair should be more than 90% determined by the local heart team with a cardiologist and cardiothoracic surgeon. Exclusion Criteria: - Pulmonary hypertension (>50 mmHg at rest). - Atrial fibrillation, either on 12-lead ECG or holter-monitoring. - Physical inability as determined by the heart team to undergo surgery. - Other life-threatening morbidity. - Higher expected surgical risks in advance, according to the dedicated heart team. - Patients with moderate to severe kidney disease (estimated glomerular filtration rate (eGFR) less than 30 mL/min). - Flail leaflet together with a left ventricular end systolic diameter (LVESD) =40 mm (no indexed value) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amsterdam Medical Center (AMC) | Amsterdam | |
Netherlands | Amphia Breda | Breda | |
Netherlands | Medisch Spectrum Twente (MST) | Enschede | |
Netherlands | Leiden University Medical Center (LUMC) | Leiden | |
Netherlands | Maastricht UMC | Maastricht | |
Netherlands | University Medical Center Utrecht (UMC Utrecht) | Utrecht |
Lead Sponsor | Collaborator |
---|---|
UMC Utrecht | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amphia Hospital, Leiden University Medical Center, Maastricht University Medical Center, Medisch Spectrum Twente, Netherlands Heart Institute |
Netherlands,
Ling LH, Enriquez-Sarano M, Seward JB, Orszulak TA, Schaff HV, Bailey KR, Tajik AJ, Frye RL. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation. 1997 Sep 16;96(6):1819-25. — View Citation
Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006 May 9;113(18):2238-44. Epub 2006 May 1. — View Citation
Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 Jan;28(2):230-68. Epub 2007 Jan 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to event: cardiovascular mortality, congestive heart failure, hospitalization, class I or class IIa indication for MV surgery | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03278574 -
Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease
|
N/A | |
Suspended |
NCT04960280 -
A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease
|
N/A | |
Recruiting |
NCT05021614 -
Valveclip® Transcatheter Mitral Valve Repair Study
|
N/A | |
Not yet recruiting |
NCT06167213 -
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
|
N/A | |
Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
Withdrawn |
NCT05040451 -
Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
|
||
Withdrawn |
NCT03714412 -
Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System
|
N/A | |
Recruiting |
NCT02592889 -
(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)
|
Phase 4 | |
Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
Not yet recruiting |
NCT01431222 -
Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery
|
Phase 4 | |
Completed |
NCT01841554 -
Cardioband With Transfemoral Delivery System
|
N/A | |
Not yet recruiting |
NCT03870516 -
Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery
|
N/A | |
Active, not recruiting |
NCT03230747 -
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
|
N/A | |
Enrolling by invitation |
NCT04031274 -
Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
|
||
Completed |
NCT05836532 -
Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
|
||
Completed |
NCT05836480 -
Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
|
||
Completed |
NCT05850026 -
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
|
||
Completed |
NCT01162083 -
Identifying an Ideal Cardiopulmonary Exercise Test Parameter
|
N/A | |
Suspended |
NCT00787293 -
Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients
|
Phase 2 | |
Recruiting |
NCT00745680 -
Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI)
|
N/A |